Table 6.
Major adverse effects observed among children with congenital toxoplasmosis during the treatment with sulfadiazine, pyrimethamine, and folinic acid, attended at Outpatient Clinic Hospital of the State University of Londrina, Londrina, Paraná, from January 2000 to December 2010.
| Adverse effects | Children (n = 29) |
|
|---|---|---|
| n | % | |
| Mild neutropeniaa (1001–1499 cells/mm3) | 4 | 13.8 |
| Moderate neutropenia b (501–1000 cells/mm3) | 7 | 24.1 |
| Severe neutropeniac (≤500 cells/mm3) | 2 | 6.9 |
| Mild megaloblastic anemia (Hemoglobin: 10.1–11.9 g/dL) | 1 | 3.5 |
| Moderate megaloblastic anemia (Hemoglobin: 8.1–10.0 g/dL) | 0 | 0.0 |
| Severe megaloblastic anemiac (Hemoglobin: ≤8.0 g/dL) | 1 | 3.5 |
| Mild thrombocytopeniac (platelets 101,000–140,000/mm3) | 1 | 3.5 |
| Moderate thrombocytopeniad (platelets 51,000–100,000/mm3) | 1 | 3.5 |
| Severe thrombocytopenia (platelets ≤ 50,000/mm3) | 0 | 0.0 |
| Mild hepatitis (AST and/or ALT ≤ two times the reference value) | 3 | 10.3 |
| Moderate hepatitis (AST and/or ALT > two times the reference value, and normal protrombine time test) | 1 | 3.5 |
| Severe hepatitis (protrombine time test < 50.0% or INR > 1.3) | 0 | 0.0 |
AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio.
a
1 patient received zidovudine (AZT) and ganciclovir concomitantly, 1 patient received ganciclovir concomitantly.
b
1 patient received zidovudine concomitantly.
c
1 patient that received zidovudine concomitantly presented severe neutropenia, severe megaloblastic anemia, and mild thrombocytopenia.
d
1 patient received ganciclovir concomitantly.